FA
IBB icon

Fagan Associates’s iShares Biotechnology ETF IBB Stock Holding History

Fagan Associates’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30,940
Closed -$4.25M – 120
2024
Q1 		$4.25M Sell
30,940
-536
-2% -$73.2K 0.8% 40
2023
Q4 		$4.28M Sell
31,476
-834
-3% -$102K 0.93% 33
2023
Q3 		$3.95M Sell
32,310
-1,068
-3% -$136K 0.96% 33
2023
Q2 		$4.24M Sell
33,378
-326
-1% -$42.3K 1.03% 29
2023
Q1 		$4.35M Sell
33,704
-734
-2% -$96.1K 1.08% 30
2022
Q4 		$4.52M Buy
34,438
+14,437
+72% +$1.87M 1.21% 29
2022
Q3 		$2.34M Sell
20,001
-188
-0.9% -$23.3K 0.65% 41
2022
Q2 		$2.38M Buy
20,189
+178
+0.9% +$21.1K 0.63% 42
2022
Q1 		$2.61M Buy
20,011
+697
+4% +$90.8K 0.53% 51
2021
Q4 		$2.95M Buy
+19,314
New +$2.99M 0.56% 51

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Fagan Associates's IBB Position: Q2 2024 in Review

Fagan Associates sold out of iShares Biotechnology ETF (IBB) in Q2 2024, closing a stake of 30,940 shares — an estimated $4.25M sold.

Fagan Associates first reported a position in IBB in Q4 2021 and held it in 10 quarters. The position peaked at $4.52M in Q4 2022. 894 funds tracked by Wall St. Rank hold IBB as of Q2 2024.

  • Fagan Associates reported no remaining iShares Biotechnology ETF position as of Q2 2024 after selling out during the quarter.
  • Fagan Associates sold 30,940 iShares Biotechnology ETF shares in Q2 2024, an estimated $4.25M.
  • Fagan Associates first reported a position in iShares Biotechnology ETF in Q4 2021 and held it in 10 quarters.
  • Fagan Associates's iShares Biotechnology ETF position peaked at $4.52M in Q4 2022.
  • 894 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2024.

Based on Fagan Associates's 13F filing for Q2 2024, filed 9 Aug 2024.